von Yanyan Shi ; Ralf Andreas Strobl ; Christian Apfelbacher ; Thomas Bahmer ; Ramsia Geisler ; Peter Heuschmann ; Anna Horn ; Hanno Hoven ; Thomas Keil ; Michael Krawczak ; Lilian Krist ; Christina Lemhöfer ; Wolfgang Lieb ; Bettina Lorenz-Depiereux ; Rafael Mikolajczyk ; Felipe Andrés Montellano ; Jens-Peter Reese ; Stefan Schreiber ; Nicole Skoetz ; Stefan Störk ; Jörg Janne Vehreschild ; Martin Witzenrath ; Eva Grill ; Ulf Günther ; Astrid Petersmann
Online first: 8 January 2021 ; Gesehen am 16.07.2021
First-line therapy for younger patients with peripheral T-cell non-Hodgkin lymphoma (T-NHL) consists of 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide (CHOEP), consolidated by high-dose therapy and autologous stem cell transplantation (auto-SCT). We hypothesized that allogeneic stem cell transplantation (allo-SCT) could improve outcomes. 104 patients with peripheral T-cell non-Hodgkin lymphoma, except ALK+ anaplastic large cell lymphoma, 18 to 60 years, all stages, and all age adjusted International Prognostic Index scores, except 0 and stage I, were randomized to 4 cycles of CHOEP and 1 cycle of dexamethasone, cytosine-arabinoside, and platinum (DHAP) followed by high-dose therapy and auto-SCT or myeloablative conditioning and allo-SCT. The primary end point was event-free survival (EFS) at 3 years. After a median follow-up of 42 months, the 3-year EFS after allo-SCT was 43%, as compared with 38% after auto-SCT. Overall survival at 3 years was 57% vs 70% after allo- or auto-SCT, without significant differences between treatment arms. None of the 21 responding patients proceeding to allo-SCT relapsed, as opposed to 13 of 36 patients (36%) proceeding to auto-SCT. Eight of 26 patients (31%) and none of 41 patients died of transplant-related toxicity after allo- and auto-SCT, respectively. The strong graft-versus-lymphoma effect after allo-SCT was counterbalanced by transplant-related mortality. This trial is registered at www.clinicaltrials.gov as #NCT00984412.
Blood Washington, DC : American Society of Hematology, 1946 137(2021), 19 vom: 13. Mai, Seite 2646-2656 Online-Ressource
von Jonas Jourdan ; Martin Plath ; Jonathan D. Tonkin ; Maria Ceylan ; Arlena Dumeier ; Georg Gellert ; Wolfram Graf ; Charles P. Hawkins ; Ellen Kiel ; Armin W. Lorenz ; Christoph D. Matthaei ; Piet F. M. Verdonschot ; Ralf C. M. Verdonschot ; Peter Haase
von Anja Drews ; A. C. de Keizer ; Hans Georg Beyer ; Elke Lorenz ; Jethro Betcke ; Wilfried G. van Sark ; Wolfgang Heydenreich ; Edo Wiemken ; Sandra Stettler ; Peter Toggweiler ; Stefan Bofinger ; Martin Schneider ; Gerd Heilscher ; Detlev Heinemann
von Hans Georg Beyer ; Elke Lorenz ; Jethro Betcke ; Anja Drews ; Detlev Heinemann ; A. C. de Keizer ; Wilfried G. van Sark ; Sandra Feige ; Stefan Bofinger ; Martin Schneider ; Gerd Heilscher ; Sandra Stettler ; Peter Toggweiler ; Edo Wiemken ; Wolfgang Heydenreich
von Anja Drews ; Elke Lorenz ; Jethro Betcke ; A. C. de Keizer ; Wilfried G. van Sark ; Hans Georg Beyer ; Wolfgang Heydenreich ; Edo Wiemken ; Sandra Stettler ; Peter Toggweiler ; Stefan Bofinger ; Martin Schneider ; Gerd Heilscher ; Detlev Heinemann
von A. C. de Keizer ; Wilfried G. van Sark ; Sandra Stettler ; Peter Toggweiler ; Elke Lorenz ; Anja Drews ; Detlev Heinemann ; Gerd Heilscher ; Martin Schneider ; Edo Wiemken ; Gerd Heydenreich ; Hans Georg Beyer
